Chemaphor Inc. announced that it has launched a stem cell regenerative therapy for pets and horses in Canada.
Chemaphor has gained access to the exclusive marketing rights for this procedure in Canada through the acquisition of a private company, of which the ultimate licensor of this regenerative stem cell therapy is Vet-Stem Inc. of California.
Chemaphor Inc. is a wellness company focused on Natural Health Enhancer (NHE) products for animals and humans.
The regenerative treatment being launched in Canada by Chemaphor harnesses an animal’s own stem cells, which Chemaphor will process at its laboratories in PEI. More than 10,000 veterinarians in Canada can now deliver a procedure that assists in repairing damaged joints or ligaments through a regenerative process.
“This is a fantastic opportunity to combine a novel, demonstrably effective treatment for suffering pets and their owners, while maintaining our focus on providing scientifically supported solutions to veterinarians and their patients,” said Paul Dick, CEO of Chemaphor.
“Prior to deciding on our first acquisition, we consulted with academic institutions, veterinarians, surgeons and other third parties in determining the fit of this opportunity with Chemaphor and its valued customers. We are delighted that we can now look towards implementing this procedure across Canada.”
David Hankinson, chairman of Chemaphor added, “We are advancing our pipeline assertively while keeping an eye on potential value-creating opportunities in the hope of rewarding our investors, who have been tremendously patient with our product development timelines.
“This stem cell regenerative treatment is exciting and allows us to confirm to our shareholders that we are now a commercial organization, with a market approved therapy complemented by a pipeline of Chemaphor-owned products.”
Source: Chemaphor
Chemaphor has gained access to the exclusive marketing rights for this procedure in Canada through the acquisition of a private company, of which the ultimate licensor of this regenerative stem cell therapy is Vet-Stem Inc. of California.
Chemaphor Inc. is a wellness company focused on Natural Health Enhancer (NHE) products for animals and humans.
The regenerative treatment being launched in Canada by Chemaphor harnesses an animal’s own stem cells, which Chemaphor will process at its laboratories in PEI. More than 10,000 veterinarians in Canada can now deliver a procedure that assists in repairing damaged joints or ligaments through a regenerative process.
“This is a fantastic opportunity to combine a novel, demonstrably effective treatment for suffering pets and their owners, while maintaining our focus on providing scientifically supported solutions to veterinarians and their patients,” said Paul Dick, CEO of Chemaphor.
“Prior to deciding on our first acquisition, we consulted with academic institutions, veterinarians, surgeons and other third parties in determining the fit of this opportunity with Chemaphor and its valued customers. We are delighted that we can now look towards implementing this procedure across Canada.”
David Hankinson, chairman of Chemaphor added, “We are advancing our pipeline assertively while keeping an eye on potential value-creating opportunities in the hope of rewarding our investors, who have been tremendously patient with our product development timelines.
“This stem cell regenerative treatment is exciting and allows us to confirm to our shareholders that we are now a commercial organization, with a market approved therapy complemented by a pipeline of Chemaphor-owned products.”
Source: Chemaphor
